Article info

Original research
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Authors

  1. Correspondence to Dr Carlos Gomez-Roca; gomez-roca.carlos{at}iuct-oncopole.fr
View Full Text

Citation

Gomez-Roca C, Cassier P, Zamarin D, et al
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Publication history

  • Accepted March 8, 2022
  • First published May 16, 2022.
Online issue publication 
May 16, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.